This paper describes four patients with undetected progressive supranuclear palsy who were referred to psychiatric facilities for treatment of late onset symptoms and signs attributed to primary psychopathology. However, subsequent neurological and neuropsychological evaluation established the diagnosis of progressive supranuclear palsy. In two patients, psychiatric symptoms preceded the onset of neurological deficits. It is our experience that because of presenting symptomatology, some patients with progressive supranuclear palsy will be referred for psychiatric consultation. The possibility of progressive supranuclear palsy should be considered in the differential diagnosis of late onset psychiatric syndromes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/00005053-198402000-00004 | DOI Listing |
Background: The hyperphosphorylation, mislocalization, and aggregation of the microtubule associated protein Tau (MAPT) is a driving force in tauopathies, a group of progressive, neurodegenerative disorders. These pathogenic intracellular aggregates, known as neurofibrillary tangles (NFTs), are a hallmark in several diseases such as frontotemporal dementia, progressive supranuclear palsy, and Alzheimer's Disease. While anti-Tau immunotherapies emphasize the clearance of extracellular Tau aggregates, they do not address the intracellular accumulation of NFTs.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Mayo Clinic, Rochester, MN, USA.
Background: The Progressive Supranuclear Palsy Quality of Life (PSP-QoL) scale is a 45-question participant-completed questionnaire used to evaluate physical and cognitive task difficulties. Participants enrolled in the ALLFTD research program are asked to complete this questionnaire annually during their study visits.
Method: PSP-QoL responses were analyzed at baseline visits.
Alzheimers Dement
December 2024
Mayo Clinic, Rochester, MN, USA.
Background: Self-administered cognitive assessments demonstrate usability and ability to detect cognitive decline in Alzheimer's disease, but usability in other neurodegenerative diseases is understudied. We investigated whether Mayo Test Drive (MTD), a self-administered multi-device compatible cognitive assessment platform, demonstrates usability and correlation with traditional neuropsychological tests in a pilot study of individuals with progressive supranuclear palsy (PSP).
Method: Eleven individuals with PSP (mean age = 69.
Front Neurol
December 2024
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Background: The Montreal Cognitive assessment (MoCA) is a well-validated global cognitive screening instrument. Its validity in progressive supranuclear palsy (PSP) has not been assessed.
Objectives: To evaluate the MoCA as an outcome measure in PSP clinical trials.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!